Passage Bio opened at $4.00, in line with its previous close of $4.00. In the last trading session, the stock traded between $3.49 and $4.09. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Passage Bio is now worth
$ 2.37
Resulting in a loss of
$ 97.63 (97.63%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
+$0.06 (+1.40%)
Day High
$4.09
Day Low
$3.49
Day Open
$4.00
Prev Close
$4.00
Volume
12,264
1W Return
15.89%
1M Return
-5.89%
3M Return
-8.94%
6M Return
-7.82%
1Y Return
-47.32%
Fundamentals
Market Cap ($ Mn)
13
PE Ratio
-
PB Ratio
3.29
PEG Ratio
-
ROE
-116.07%
ROCE
-75.43%
EPS (TTM)
$-1.47
Investment Returns
1 Week
15.89%
1 Month
-5.89%
3 Months
-8.94%
6 Months
-7.82%
9 Months
-53.70%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
0.0
Sep 26
Updates
21Oct
Halper Sadeh investigates Passage Bio merger for shareholder rights
Halper Sadeh LLC investigates Passage Bio's merger with Remix Therapeutics. Shareholders expected to own approximately 7% of the combined company. Probe alleges failure to obtain best price and disclose material info. Insiders may receive benefits not available to ordinary shareholders.
22 days ago
10Aug
Passage Bio Q2 Results: EPS beats estimates, losses narrow YoY
Passage Bio delivered a stronger-than-expected second quarter with EPS of $(2.44), beating estimates by 29.68%. The company also showed a 17.57% year-over-year improvement in losses compared to the previous year's $(2.96) per share deficit.
Passage Bio and Remix Therapeutics have signed an all-stock merger agreement, with the combined entity to operate as Remix Therapeutics on Nasdaq under the ticker RMTX. The transaction includes a $100 million private placement financing led by Decheng Capital, with participation from Lynx1 Capital Management and Forge Life Science Partners.
